

DAFTAR PUSTAKA

1. WHO. Global Tuberculosis Report. January. United States; 2023. 1–19 p.
2. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Laporan Program Penanggulangan Tuberkulosis Tahun 2022. Kemenkes RI. 2023;1–156.
3. Bloom BR, Atun R, Cohen T, Dye C. Tuberculosis. In: Major Infectious Disease. Third. Washington, D .C: World Bank Book; 2017. p. 233–67.
4. Churchyard G, Kim P, Shah NS, Rustumjee R, Gandhi N, Mathema B, et al. What We Know about Tuberculosis Transmission: An Overview. *J Infect Dis*. 2017;216(Suppl 6):S629–35.
5. Raviglione MC, O'Brien RJ. Tuberculosis. In: Kasper DL, Fauci AS, editors. *Harrison's Infectious Disease*. United States: McGraw-Hill Education.; 2010. p. 615–23.
6. Kemenkes RI. Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis. Burhan E, Sueroto A, Isbaniah F, editors. Jakarta Pusat; 2020.
7. Carabalí-Isajar ML, Rodríguez-Bejarano OH, Amado T, Patarroyo MA, Izquierdo MA, Lutz JR, et al. Clinical manifestations and immune response to tuberculosis. *World J Microbiol Biotechnol*. 2023;39(8):1–26.
8. de Martino M, Lodi L, Galli L, Chiappini E. Immune Response to Mycobacterium tuberculosis: A Narrative Review. *Front Pediatr*. 2019;7(August):1–8.
9. Maison DP, Department. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. *Tuberc Pathophysiol anti-VEGF Interv David*. 2022;28(May):100318.
10. Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. *Int J Mol Sci*. 2023;24(6).
11. Gopalaswamy R, Dusthacker VNA, Kannayan S, Subbian S. Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance. *J Respir*. 2021;1(2):141–64.
12. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. *Clin Infect Dis*. 2009;49(9):1350–7.
13. H Ancira-Moreno M; Smith NLF. Deramne Pleural Tuberculosis. *Eff grain boundaries paraconductivity YBCO*. 2002;1(1):1–11.
14. Light RW. Tuberculous pleural effusion. *Turk Toraks Derg*. 2015;16(1):1–9.
15. Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CFN. Tuberculous pleural effusions: Advances and controversies. *J Thorac Dis*. 2015;7(6):981–91.
16. Light RW. Update on tuberculous pleural effusion. *Respirology*. 2010;15(3):451–8.
17. Jeon D. Tuberculous pleurisy: An update. *Tuberc Respir Dis (Seoul)*. 2014;76(4):153–9.
18. Light R. Clinical Manifestations and Useful Tests. In: *PLEURAL DISEASES*. 6th ed. USA: LIPPINCOTT WILLIAMS & WILKINS; 2013. p. 86–111.
19. Light R. Tuberculous Pleural Effusion. In: *PLEURAL DISEASES*. USA; 2013. p. 247–59.
20. Pleural Disease Guideline. *Br Thorac Soc*. 2010;
21. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Jakarta; 2020.
22. Travaglino F. The Utility of Pyrogenic Cytokine (IL-1 β , TNF- α and IL-6) Detection In Risk Stratification of Critically Ill Febrile Patients in Emergency Department. *J Mol Biomark Diagn*. 2014;05(05):1–5.
23. Perhimpunan Dokter Paru Indonesia. Tuberkulosis Pedoman Diagnosis dan

- Penatalaksanaan di indoneia. 2021.
24. Gill CM, Dolan L, Piggott LM, McLaughlin AM. New developments in tuberculosis diagnosis and treatment. *Breathe*. 2022;18(1):1–15.
 25. Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. *PLoS One*. 2008;3(7):3–7.
 26. Zhao T, Chen B, Xu Y, Qu Y. Clinical and pathological differences between polymorphonuclear-rich and lymphocyte-rich tuberculous pleural effusion. *Ann Thorac Med*. 2020;15(2):76–83.
 27. Abbas AK, Litchman AH, Pillai S. *Imunitas Alami*. In: *Imunologi Dasar Abbas*. 2016. p. 27–54.
 28. Gaffney E, Murphy D, Walsh A, Connolly S, Basdeo SA, Keane J, et al. Defining the role of neutrophils in the lung during infection: Implications for tuberculosis disease. *Front Immunol*. 2022;13(September):1–14.
 29. Alemán M, Schierloh P, De La Barrera SS, Musella RM, Saab MA, Baldini M, et al. Mycobacterium tuberculosis triggers apoptosis in peripheral neutrophils involving Toll-like receptor 2 and p38 mitogen protein kinase in tuberculosis patients. *Infect Immun*. 2004;72(9):5150–8.
 30. Alcantara CA, Glassman I, Nguyen KH, Parthasarathy A, Venketaraman V. Neutrophils in Mycobacterium tuberculosis. *Vaccines*. 2023;11(3):1–11.
 31. Lin MT, Wang JY, Yu CJ, Lee LN, Yang PC. Mycobacterium tuberculosis and polymorphonuclear pleural effusion: Incidence and clinical pointers. *Respir Med*. 2009;103(6):820–6.
 32. Choi H, Chon HR, Kim K, Kim S, Oh KJ, Jeong SH, et al. Clinical and laboratory differences between lymphocyte- and neutrophil-predominant pleural tuberculosis. *PLoS One*. 2016;11(10):1–10.
 33. World Health Organization. *Global Tuberculosis Report*. World Health Organization; 2022. 1–33 p.
 34. Ogoina D. Fever, fever patterns and diseases called “fever” - A review. *J Infect Public Health* [Internet]. 2011;4(3):108–24. Available from: <http://dx.doi.org/10.1016/j.jiph.2011.05.002>
 35. Panteleev A V., Nikitina IY, Burmistrova IA, Kosmiadi GA, Radaeva T V., Amansahedov RB, et al. severe tuberculosis in humans correlates best with neutrophil abundance and lymphocyte deficiency and does not correlate with antigen-specific CD4 T-cell response. *Front Immunol*. 2017;8(AUG):1–16.
 36. Lim JU, Lee JH, Kim JS, Hwang Y II, Kim T hyung, Yong S, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. 2017;2465–75.
 37. Feng JY, Huang SF, Ting WY, Chen YC, Lin YY, Huang RM, et al. Gender differences in treatment outcomes of tuberculosis patients in Taiwan: A prospective observational study. *Clin Microbiol Infect*. 2012;18(9).
 38. World Health Organization. *Global Tuberculosis Report*. 2024. 8 p.
 39. Flynn JL, Ernst JD. Immune responses in tuberculosis. *Curr Opin Immunol*. 2000;12(4):432–6.
 40. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, et al. Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation. *J Immunol*. 2004;173(10):6098–108.
 41. Calippe B, Douin-Echinard V, Laffargue M, Laurell H, Rana-Poussine V, Pipy B, et al. Chronic Estradiol Administration In Vivo Promotes the Proinflammatory Response of Macrophages to TLR4 Activation: Involvement of the Phosphatidylinositol 3-Kinase Pathway. *J Immunol*. 2008;180(12):7980–8.
 42. Gupta M, Srikrishna G, Klein S, Bishai WR. Genetic and hormonal mechanisms

- underlying sex-specific immune responses in tuberculosis. *Trends Immunol.* 2022;
43. Jee SH, Golub JE, Jo J, Park IS, Ohrr H, Samet JM. Smoking and risk of tuberculosis incidence, mortality, and recurrence in South Korean men and women. *Am J Epidemiol.* 2009;170(12):1478–85.
 44. Guzik K, Skret J, Smagur J, Bzowska M, Gajkowska B, Scott DA, et al. Cigarette smoke-exposed neutrophils die unconventionally but are rapidly phagocytosed by macrophages. *Cell Death Dis.* 2011;2(3):1–11.
 45. Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: Prospective cohort study. *Am J Respir Crit Care Med.* 2009;180(5):475–80.
 46. Ferreiro L, José ES, Valdés L. Tuberculous Pleural Effusion. *Arch Bronconeumol.* 2014;435–443.
 47. Bielsa S, Palma R, Pardina M, Esquerda A, Light RW, Porcel JM. Comparison of polymorphonuclear- And lymphocyte-rich tuberculous pleural effusions. *Int J Tuberc Lung Dis.* 2013;17(1):85–9.
 48. Lee J, Lim JK, Yoo SS, Lee SY, Cha SI, Park JY, et al. Different characteristics of tuberculous pleural effusion according to pleural fluid cellular predominance and loculation. *J Thorac Dis.* 2016;8(8):1935–42.
 49. Feleke BE, Feleke TE, Biadglegne F. Nutritional status of tuberculosis patients, a comparative cross-sectional study. *BMC Pulm Med.* 2019;19(1):1–9.
 50. Filippo K De, Henderson RB, Laschinger M, Hogg N. Neutrophil Chemokines KC and Macrophage-Inflammatory Protein-2 Are Newly Synthesized by Tissue Macrophages Using Distinct TLR Signaling Pathways. *Immunology.* 2014;2008.
 51. Lyadova I V. Neutrophils in Tuberculosis: Heterogeneity Shapes the Way? *Mediators Inflamm.* 2017;2017.
 52. Muefong CN, Sutherland JS. Neutrophils in Tuberculosis-Associated Inflammation and Lung Pathology. *Front Immunol.* 2020;11(May):1–9.
 53. Barry S, Breen R, Lipman M, Johnson M, Janossy G. Impaired antigen-specific CD4+ T lymphocyte responses in cavitary tuberculosis. *Tuberculosis [Internet].* 2009;89(1):48–53. Available from: <http://dx.doi.org/10.1016/j.tube.2008.07.002>
 54. Manuel HE, Luis AÁC, Xavier BP, José MRM, Manuel RG, Salvi SS. Influence of Thoracentesis and Pleural Biopsy on Biochemical Parameters and Cytology of Pleural Fluid. *Arch Bronconeumol ((English Ed.* 2007;43(5):277–82.
 55. Shaw JA, Diacon AH, Koegelenberg CFN. Tuberculous pleural effusion. *Respirology.* 2019;24(10):962–71.
 56. Koh WJ. Progression of tuberculous pleurisy: From a lymphocyte-predominant free-flowing effusion to a neutrophil-predominant loculated effusion. *Tuberc Respir Dis (Seoul).* 2017;80(1):90–2.
 57. Aiello A, Najafi-Fard S, Goletti D. Initial immune response after exposure to *Mycobacterium tuberculosis* or to SARS-COV-2: similarities and differences. *Front Immunol.* 2023;14(August):1–24.